Intercytex Share Discussion Threads

[the_doctor] 29/5/2010 16:50

Hyper

re patents, no! Whoever owns the rights will own it. That's clearly been sold. It doesnt matter who is listed in the system really. They change that later, or not at all in many cases.

patents promote invention, not stifle it.
it specifically helps to ensure that inventors can get a return on the time, effort and money they put in. You dont want to develop a product then find 10 others copying it when you get to market!
It very much helps 'development of ideas into real world products'
The fact that a few copycat ideas are held off the market for a while is irrelevant IMO. If their product is good enough, they can get a license from the patent owner, but copycats wont

'So when do we get financial details from 'Regenerative Medicine Assets Limited' ? and how they are spending our money'

dont know. I forget what the last statement said.
Dont expect much!

[bogzy2] 29/5/2010 16:13

Repair, Replace, Restore, Regenerate
The Manchester Biomedical Research Centre is pleased to announce a
one day meeting:
Clinical Aspects of
Regenerative Medicine
21st June 2010 (9:00am - 4:00pm)
Bringing together academics, clinician scientists and industry representatives
to focus on current efforts to bring these innovative therapies to the clinic and
the 'green shoots' of the Regenerative Medicine industry. The programme
includes:
• Tales from the Frontline
Dr. Paul Kemp, Founder & CSO, Intercytex
• Cellular Therapy of Cancer: Bench to Bedside
Prof. Robert Hawkins, Cellular Therapeutics Unit, University of Manchester
• Stem Cell Therapy of Inborn Errors of Metabolism
Dr. Robert Wynn, Royal Manchester Children's Hospital
• Development of natural acellular scaffolds: From research to grafting
Dr. Paul Rooney, NHS Blood & Tissue Transplant Services
• Regener8 Case Study: Acellular Allogeneic Cardiac Valves
Prof. Eileen Ingham, University of Leeds
• Stem Cell Therapies for Kidney Disease
Dr. Trisha Murray, University of Liverpool Stem Cell Consortium
• Title to be confirmed
Dr. Tony Metcalfe, Head of Scientific Opportunities, Renovo Group
The Nowgen Centre Register: [e-mail]
Grafton Street Info: [e-mail]
Manchester M13 9WL Phone: [phone]

[the_doctor] 29/5/2010 14:36

'they should have sold those assets while we were listed'

why? makes no difference

ICX essentially = 'Regenerative Medicine Assets Limited'
If they wanted to rip you off, they still could

The issue is whether assets were sold on the cheap.
The house broker was involved, so probably not.
However, given that some of the old employees have been taken on by the buyer, there is a greater risk that they were incentivised to help them out!
How hard did they search for buyers for example?

All said though, any other players in the industry knew these assets were for sale, so they'd have jumped in if they thought they were being sold too cheaply.

Best thing for holders to do is call the buyer, Kemp, the house broker and other directors to discuss.


'The Patent applications were in the name of ICX in fact if you do a Patent search they still are. So legally they still belong to us'

revisit your law Hyper!

[the_doctor] 29/5/2010 13:51

Yes hyper and they've sold many/all of the assets on!

[tradermel] 29/5/2010 13:42

Fair enough :-)

[the_doctor] 29/5/2010 13:41

tradermel - that was obviously directed at those that talked nonsense. One poster in particular made all sorts of silly comments
Investors do of course have a right to feel aggreived.
I've actually put some effort into digging up info that could help assess whether you've been ripped off or not.

[the_doctor] 29/5/2010 13:39

Well done

So, that fits my question:

"Whether one of the ICX managers has been given part of their new company or runs it, who knows!?"

All said though, it is natural that Kemp would be taken on to run it.

However, given he has remained in, it does raise the question of whether he stood to benefit more by letting ICX go into liquidation and allowing parts to be sold off (potentially to 'mates') rather than push for a better price with others that might for example have sacked him

[bogzy2] 29/5/2010 13:30

Who does he work for?

Whats happening at the McGowen Institute?
Tuesday May 25th 2010

Grant Of The Month
PI
Alan J. Russell, Stephen F. Badylak, J. Peter Rubin, Bernard J. Costello, Prashant N. Kumta, Charles Sfeir, Paul Kemp

Title
Limb Salvage and Regenerative Medicine Initiative

Co-Investigators Thomas Gilbert
Description
This program will advance technologies that return wounded personnel to active duty, restore their limb, muscular, and skin form or function, and assist them in reclaiming independence, dignity, and self-confidence in the tasks of daily living. The program will fund rapid research, development and validation of innovative technologies to improve the clinical outcome of burn and blast injured personnel. Technology refers to integrated systems based on combinations of hardware, software, pharmaceuticals, biologics, and surgical methods. This initiative will advance medical technologies from their existing levels of maturation, through FDA trials and approval, to significantly improve upon current standard treatments for use by the Department of Defense, Veteran's Administration, public health, and commercial health systems.

Program Areas:

1) Muscle Tissue Regeneration with the Use of Biologic Scaffolds for Patients Suffering from Massive Loss of Skeletal Muscle Tissue

2) Bone Scaffolding for Craniofacial Regeneration

3) Research and Implementation of Clinical Trials of Allogenic Human Dermal Fibroblasts for Remodeling Scar contractors using ICX-RHY Technology

Source
DOD

Term
04/01/10-3/31/12

Amount:
$12,183,808

[bogzy2] 28/5/2010 23:54

Should we be given more information or are the people involved above justice?

[bogzy2] 28/5/2010 23:20

scroll to bottom of page

Congress Day 3 Thursday 13 May 2010 - AFTERNOON PLENARY SESSION
5.20pm
Panel session: an industry-wide strategy for finding the way forward in regenerative medicine
Encompassing business, philanthropy and patient advocacy into regenerative medicine to retain momentum in the industry
Re-evaluating the regulatory landscape and how to navigate it.
Business models and shared resources – the collaborative way forward.
Greg Bonfiglio,Managing Director,
Proteus Venture Partners
Dr Jason Gardner,Vice President, Head of Stem Cell Discovery Performance Unit,
GlaxoSmithKline
Geoff McKay,Chief Executive Officer,
Organogenesis
Bernard Siegel,Executive Director,
Genetics Policy Institute
Dr Paul Kemp,Chief Executive Officer,
Regenerative Solutions Ltd

[bogzy2] 28/5/2010 00:45

World Stem Cells & Regenerative Medicine Congress 11-13 May 2010 London uk
Congress Day 3 Thursday 13 May 2010 afternoon plenary session
Dr Paul Kemp - Chief Executive officer
Regenerative Solutions LTD

[the_doctor] 21/5/2010 15:36

prob them



If you want to speak with them



They strike me as a loaded family that were perhaps investors in ICX (shareholder list?). The company was wound down, because it didnt have sufficient funds to be a viable business, but some of the assets were still viable.
It seems the Caldwells have got sufficient cash to try to get one of the assets furthered.

Whether one of the ICX managers has been given part of their new company or runs it, who knows!?

[the_doctor] 21/5/2010 15:32

Regenerative Solutions Limited was set up on 15th Feb 2010

It is based at the same place as this

has phone number there

which is registered here (their accountants)
FODEN INVESTMENTS LIMITED
78 CHORLEY NEW ROAD
BOLTON
BL1 4BY

The only director shown is MARK JAMES CALDWELL and a female relative

He also runs B3 PROPERTIES (CARRWOOD) LIMITED
with PAUL ANTHONY STEWART / 20/05/2010
PAUL CONNOR
DAVID ANDREW CALDWELL

No obvious connections there or signs of the company selling assets to the old management on the cheap.

However, it is unclear why Mr Caldwell would want to start a company to buy Vavelta?

Anyone interested could call him on the number in the link above

[whibbled] 21/5/2010 10:36

APRIL PRESS RELEASE

Sale of Vavelta
19th April 2010

Regenerative Medicine Assets Limited (formerly Intercytex Group plc) today announces that it has completed the sale of certain assets related to its skin repair and rejuvenation product, Vavelta, from its wholly owned subsidiary Intercytex Limited to Regenerative Solutions Limited for a nominal sum. In addition, it has issued Regenerative Solutions Limited with an option to acquire the entire share capital of Intercytex Limited. In exchange for these assets, Regenerative Medicine Assets Limited has entered into an agreement to surrender its leases on its registered office in Manchester on fulfilment of certain conditions. Commitments under the two leases on this property totalled £1.58m at 31 December 2009.

Regenerative Medicine Assets Limited has now completed all transactions it anticipated in the circular to shareholders dated 7 December 2009. However, certain of these transactions included milestone payments and payments in escrow which have yet to be received. Therefore, the Company continues to work to ensure receipt of these payments.

[the_doctor] 20/4/2010 08:02

Very similar process happening an Neuropharm.

After failure of a PIII that everything hangs off, some of these company's have no future but liquidation.

[larmor] 16/4/2010 12:25

I really can't comment on the financial debacle that much but thought I could give a little bit of basic background on the pivotal Phase III trial. As you probaly know, the Phase III SKN trial failed to demonstrate a statistically significant difference between the test article and placebo once the "blinding" was removed. The possible confounding factor was that on both arms of the study patients also received a standard treatment for leg ulcers called 4 layer bandaging. Although this technique is common it is often not done that well. Going to a hospital clinic on a weekly basis and getting this done "properly" may well have led to an improvement in some cases in the placebo arm of the study and if you can't demonstrate superiority over a much cheaper, standard treatment then you are going to be in trouble.

This was a very small company (80-100 employees at peak) and always a high risk. Given a succesful outcome to the Phase III I believe the original game plan was to be bought out by a competitor or big Pharma. I agree with t_d that if you want to see a real fraud in action take a look at what happened at MDX! Nevertheless, I feel sorry for people who lost here.

Regards

Larmor

[the_doctor] 16/4/2010 12:08

THERE IS NO NEW COMPANY! ICX IS BEING WOUND DOWN. ASSETS SOLD OFF, NOTHING!

Until it is wound down, you still own shares in this private company. Any remaining cash will then be distributed.

[philwill] 16/4/2010 11:51

not a chance squinty